



**UNIVERSITI PUTRA MALAYSIA**

**CB1-MEDIATED EFFECTS OF DELTA-9-TETRAHYDROCANNABINOL  
( $\Delta^9$ THC) ON NEURONAL PROTEIN EXPRESSIONS IN THE  
HIPPOCAMPUS OF MALE *SPRAGUE DAWLEY* RATS**

**FATIN NADZIRAH BINTI ZAKARIA**

**FPSK(m) 2013 2**



**CB<sub>1</sub>-MEDIATED EFFECTS OF DELTA-9-TETRAHYDROCANNABINOL  
( $\Delta^9$ THC) ON NEURONAL PROTEIN EXPRESSIONS IN THE HIPPOCAMPUS  
OF MALE *SPRAGUE DAWLEY* RATS**

**By**

**FATIN NADZIRAH BINTI ZAKARIA**

**Thesis submitted to the School of Graduate Studies, Universiti Putra Malaysia, in  
Fulfilment of the Requirement for the Degree of Master of Science**

**January 2013**

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of the requirement for the degree of Master of Science

**CB<sub>1</sub>-MEDIATED EFFECTS OF DELTA-9-TETRAHYDROCANNABINOL ( $\Delta^9$ THC) ON NEURONAL PROTEIN EXPRESSIONS IN THE HIPPOCAMPUS OF MALE *SPRAGUE DAWLEY* RATS**

By

**FATIN NADZIRAH BINTI ZAKARIA**

**January 2013**

**Chairman : Mohamad Aris Bin Mohd Moklas, PhD**

**Faculty : Medicine and Health Sciences**

Neuroplasticity refers to the ability of the brain to respond as a result of a certain experience. Delta-9-tetrahydrocannabinol ( $\Delta^9$ THC), originally extracted from the female plant of *Cannabis sativa* is regarded as the most active psychotropic ingredient of cannabis. *Cannabis sativa*, the largest variety grows in both tropical and temperate climates.  $\Delta^9$ THC has been shown to affect sensory perception, cognition and memory, reward, appetite, motor coordination and attention. A recent review of references indicates that  $\Delta^9$ THC plays an important role in neuronal plasticity. *In-vitro* and *in-vivo* studies showed that administration of  $\Delta^9$ THC modulates several neuronal protein expressions involved in synaptic plasticity in hippocampal region. Previous studies have provided clues on how hippocampus plays an important role in memory process. However the molecular alteration and cellular mechanism leading to neuronal plasticity

are not yet well understood. Therefore, the objectives of this study were to evaluate the effects of acute and chronic  $\Delta^9$ THC treatment on total ERK1 and ERK2 (p44 and p42 MAP kinase), p-ERK1 and p-ERK2 (p-p44 and p-p42 MAP kinase), CREB, p-CREB and *c-fos* protein levels in the rat hippocampus of brain by studying the CB<sub>1</sub> receptor mechanism which includes the receptor agonist and antagonist. These proteins are thought to be involved in neuronal plasticity. This study was done in 3 experiments. Experiment 1 and 2, the rats were divided into 4 groups which were control group and three treated groups (0.5, 1.0 and 2.0 mg/kg  $\Delta^9$ THC) respectively. For acute treatment (experiment 1), the rats in control group received vehicle (2% ethanol + 0.9% NaCl) only while for treated group, the rats received 0.5, 1.0 and 2.0 mg/kg of  $\Delta^9$ THC which were administered every 48 hours for 7 days. For chronic treatment (experiment 2),  $\Delta^9$ THC (0.5, 1.0 and 2.0 mg/kg) were administered every 48 hours for 21 days. All drugs and vehicle were administered via intraperitoneal injection (i.p.). The volume of i.p. injection was 0.1 ml/100 g body weight. Based on the chronic study, 2.0 mg/kg  $\Delta^9$ THC which was the optimum dose were used in the combination treatment (experiment 3) to study the effect of chronic  $\Delta^9$ THC with pretreatment CB<sub>1</sub> antagonist SR141716A (rimonabant). All drugs solution was prepared immediately prior to the experiment. The data were corrected on the basis of  $\beta$ -actin levels to normalize possible differences between each loading volume. The protein levels were presented as percentage changes compared with control group, designated as 100%. One-way ANOVA was performed followed by a post-hoc Tukey's Multiple Comparison Test where applicable for inter-group comparison, with  $P < 0.05$  considered a significant difference. The result showed that acute  $\Delta^9$ THC treatment at all doses modulates the levels of ERK1, ERK2 ( $P < 0.01$ ),

p-ERK1 (P<0.05; P<0.01), p-ERK2 (P<0.01), CREB and *c-fos* (P<0.05; P<0.01) proteins. However, only  $\Delta^9$ THC at 0.5 mg/kg modulates the level of p-CREB. These findings produce inconclusive results and future investigation needs to be explored. Meanwhile, for chronic treatment, administration of  $\Delta^9$ THC also modulates the levels of ERK1 (P<0.05; P<0.001), ERK2 (P<0.01), CREB, p-CREB (P<0.01) and *c-fos* (P<0.05) protein levels. There is a reduction in the level of p-ERK1 at  $\Delta^9$ THC 1.0 mg/kg. Generally, it is supposed to be increased since it had been noticed that  $\Delta^9$ THC at 2.0 mg/kg showed significant differences. The mechanism underlying these findings remains unclear and is considered an inconclusive result. The protein expression was also studied to determine whether the changes observed due to CB<sub>1</sub> receptor activation using selective antagonist SR141716A. Based on the results obtained, pre-treatment with CB<sub>1</sub> antagonist SR141716A failed to alter the  $\Delta^9$ THC-induced effect on ERK1 and *c-fos* expressions. Interestingly, these effects can be reversed by SR141716A on ERK2, p-ERK1, p-ERK2 and p-CREB proteins. In conclusion, the present data suggest that synthesis of ERK1 and *c-fos* are not CB<sub>1</sub> mediated effects but synthesis of ERK2 and activation of ERK as well as CREB by  $\Delta^9$ THC are through CB<sub>1</sub> mediated effect pathways.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

**KESAN PERANTARA CB<sub>1</sub> DELTA-9-TETRAHYDROCANNABINOL ( $\Delta^9$ THC)  
TERHADAP PARAS PROTEIN DI DALAM HIPOKAMPUS TIKUS *SPRAGUE*  
*DAWLEY* JANTAN**

Oleh

**FATIN NADZIRAH BINTI ZAKARIA**

**Januari 2013**

**Pengerusi : Mohamad Aris Bin Mohd Moklas, PhD**

**Fakulti : Perubatan Dan Sains Kesihatan**

Neuroplastisiti adalah merujuk kepada keupayaan otak untuk bertindak balas sebagai hasil daripada pengalaman yang tertentu. Delta-9-tetrahydrocannabinol ( $\Delta^9$ THC), diekstrak secara semulajadi daripada tumbuhan *Cannabis sativa* spesis betina yang dianggap sebagai bahan psikotropik yang paling aktif. *Cannabis sativa* merupakan tumbuhan yang tumbuh dalam iklim tropika dan zon iklim sederhana.  $\Delta^9$ THC telah terbukti mempengaruhi deria persepsi, kognitif dan ingatan, ganjaran, selera, koordinasi motor dan penumpuan. Rujukan kajian terkini menunjukkan bahawa  $\Delta^9$ THC memainkan peranan yang penting dalam keplastikan sinaps. Kajian *in-vivo* dan *in-vitro* menunjukkan bahawa suntikan  $\Delta^9$ THC memodulasi beberapa protein dimana ia terlibat dalam keplastikan sinaps di bahagian hipokampus. Kajian terdahulu memberi petunjuk tentang bagaimana hipokampus memainkan peranan yang penting di dalam proses ingatan. Walaubagaimanapun, pengubahsuaian molekul dan mekanisma sel yang

membawa kepada keplastikan sinaps masih belum difahami sepenuhnya. Justeru, objektif kajian ini adalah untuk menilai kesan rawatan  $\Delta^9$ THC akut dan kronik bagi ERK1 dan ERK2 (p44 MAP kinase), p-ERK1 dan p-ERK2 (p-p44 dan p-p42 MAP kinase), CREB, p-CREB dan *c-fos* dalam hipokampus tikus dengan mengkaji mekanisme reseptor CB<sub>1</sub> termasuk reseptor agonis dan reseptor antagonis. Protein-protein ini dianggap terlibat dalam keplastikan sinaps. Kajian ini dilakukan dalam 3 eksperimen. Bagi eksperimen 1 dan 2, tikus telah dibahagikan kepada empat kumpulan iaitu kumpulan kawalan dan 3 kumpulan yang dikaji (0.5, 1.0 and 2.0 mg/kg). Untuk rawatan akut (eksperimen 1), tikus dalam kumpulan kawalan menerima ejen pelarut (2% ethanol + 0.9% NaCl) sahaja manakala bagi kumpulan kajian, tikus menerima 0.5, 1.0 dan 2.0 mg/kg  $\Delta^9$ THC dan telah disuntik setiap 48 jam selama 7 hari. Untuk rawatan kronik (eksperimen 2),  $\Delta^9$ THC (0.5, 1.0 dan 2.0 mg/kg) telah disuntik setiap 48 jam selama 21 hari. Semua bahan aktif dan ejen pelarut telah diberi melalui suntikan intra peritoneum (i.p). Jumlah suntikan i.p adalah 0.1 ml/100 g daripada berat badan. Berdasarkan kajian kronik, 2.0 mg/kg  $\Delta^9$ THC yang merupakan dos optimum telah digunakan dalam kajian gabungan (eksperimen 3) untuk mengkaji kesan kronik  $\Delta^9$ THC dengan pra-rawatan CB<sub>1</sub> antagonis SR141716A (rimonabant). Semua larutan bahan aktif disediakan sejeurus sebelum eksperimen. Data diperbetulkan berdasarkan paras  $\beta$ -aktin untuk menormalkan perbezaan yang mungkin diantara setiap isipadu muatan. Paras protein telah diterjemahkan sebagai perubahan peratusan berbanding dengan kumpulan kawalan, yang ditetapkan sebagai 100%. One-way ANOVA telah dijalankan diikuti dengan Ujian Perbandingan Pelbagai Tukey pos-hoc dimana ia digunapakai untuk perbandingan antara kumpulan, dengan  $P < 0.05$  dianggap sebagai perbezaan yang signifikan. Hasil menunjukkan bahawa rawatan akut  $\Delta^9$ THC pada setiap dos

memodulasi paras protein ERK1, ERK2 ( $P < 0.01$ ), p-ERK1 ( $P < 0.05$ ,  $P < 0.01$ ), p-ERK2 ( $P < 0.01$ ), CREB dan *c-fos* ( $P < 0.05$ ,  $P < 0.01$ ). Walaubagaimanapun, hanya  $\Delta^9$ THC dos 0.5 mg/kg memodulasi paras protein p-CREB. Penemuan ini menghasilkan keputusan yang tidak dapat disimpulkan dan kajian lanjutan perlu dijalankan. Sementara itu, untuk rawatan kronik, suntikan  $\Delta^9$ THC juga memodulasi paras protein ERK1 ( $P < 0.05$ ,  $P < 0.001$ ), ERK2 ( $P < 0.01$ ), CREB, p-CREB ( $P < 0.01$ ) and *c-fos* ( $P < 0.05$ ). Terdapat penurunan paras protein p-ERK1 pada dos 1.0 mg/kg  $\Delta^9$ THC. Secara umum, paras protein tersebut sepatutnya meningkat apabila terdapat perbezaan yang signifikan pada dos 2.0 mg/kg  $\Delta^9$ THC. Mekanisma di sebalik penemuan ini masih tidak jelas dan dianggap sebagai keputusan yang tidak dapat disimpulkan. Ekspresi protein juga dikaji untuk menentukan samada perubahan yang diperhatikan adalah melalui pengaktifan reseptor CB<sub>1</sub> menggunakan antagonis SR141716A. Berdasarkan keputusan yang diperolehi, pra-rawatan dengan CB<sub>1</sub> antagonis SR141716A gagal mengubah kesan  $\Delta^9$ THC yang teraruh pada protein ERK1 dan *c-fos*. Menariknya, kesan ini boleh diterbalikkan oleh SR141716A pada protein ERK2, p-ERK1, p-ERK2 dan p-CREB. Kesimpulannya, sintesis ERK1 dan *c-fos* adalah bukan kesan perantara CB<sub>1</sub>, akan tetapi, sintesis ERK2, pengaktifan ERK dan juga CREB oleh  $\Delta^9$ THC adalah melalui kesan perantara CB<sub>1</sub>.



## ACKNOWLEDGEMENTS

First and foremost, I would like to dedicate my deepest thank to Allah S.W.T for blessing me with patience and determination to make this study completed successfully.

I would like to express my deep gratitude to my supervisor, Dr Mohamad Aris Bin Mohd Moklas, for his constant valuable ideas, advices, guidance and support throughout the whole production of this project. Without the help and support from him, this project may not have been completed with fulfilling expectations.

A big thanks to co-supervisor, Dr Mohamad Taufik Hidayat Bin Bahalruddin and Dr Che Norma Binti Mat Taib for their continuous ideas, helps and advises. Sincere appreciation is extended to all seniors in the laboratory for their immeasurable supports, assistance and encouragement.

My utmost gratitude is extended to all staffs of Anatomy Department, Cell Signaling laboratory, and Animal House who have been directly or indirectly involved in this study. Your generosity, help and valuable time are highly appreciated. My heartfelt appreciation goes to my family and friends for their moral support and encouragement throughout my study.

Last but not least, I owe my sincere thanks to Graduate Research Fellowship (GRF) for the scholarship awarded for my study. Highest appreciation also goes to Fundamental Research Grant Scheme (FRGS) from Ministry of Higher Education for their grant support of this project.

## APPROVAL

I certify that an Examination Committee has met on 09/01/2013 to conduct the final examination of Fatin Nadzirah Binti Zakaria on her Master of Science thesis entitled “CB<sub>1</sub>-mediated effect of Delta-9-tetrahydrocannabinol ( $\Delta^9$ THC) on neuronal protein expressions in the hippocampus of male *Sprague dawley* rats” in accordance with Universiti Pertanian Malaysia (Higher Degree) Act 1980 and Universiti Pertanian (Higher Degree) Act 1981. The committee recommends that the student be awarded the degree of Master of Science.

Members of the Examination Committee are as follows:

**Roslida Binti Abd Hamid@Abd Razak, PhD**

Dr

Faculty Of Medicine And Health Sciences  
Universiti Putra Malaysia  
(Chairman)

**Mohd Roslan Bin Sulaiman, PhD**

Professor

Faculty Of Medicine And Health Sciences  
Universiti Putra Malaysia  
(Internal Examiner)

**Zuraini Binti Ahmad, PhD**

Associate Professor

Faculty Of Medicine And Health Sciences  
Universiti Putra Malaysia  
(Internal Examiner)

**Nasaruddin Bin Abdul Aziz , PhD**

Professor

Kuliyah Of Medicine And Health Sciences  
Insaniah University College  
(External Examiner)

---

**SEOW HENG FONG, PhD**

Professor and Deputy Dean  
School of Graduate Studies  
Universiti Putra Malaysia  
Date:

## APPROVAL

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

**Mohamad Aris Bin Mohd Moklas, PhD**

Senior Lecturer  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Chairman)

**Mohamad Taufik Hidayat Bin Bahalruddin, PhD**

Senior Lecturer  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Member)

**Che Norma Binti Md Taib, PhD**

Senior Lecturer  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Member)

---

**BUJANG BIN KIM HUAT, PhD**

Professor and Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date :

## DECLARATION

I declare that the thesis is my original work except for the quotations and citations which have been duly acknowledge. I also declare that it has not been previously or concurrently submitted for any other degree at Universiti Putra Malaysia or at any other institution.



---

**FATIN NADZIRAH BINTI ZAKARIA**

Date: 9 January 2013

## TABLE OF CONTENTS

	<b>Page</b>
<b>ABSTRACT</b>	ii
<b>ABSTRAK</b>	v
<b>ACKNOWLEDGEMENTS</b>	viii
<b>APPROVAL</b>	ix
<b>DECLARATION</b>	xi
<b>LIST OF TABLES</b>	xiv
<b>LIST OF FIGURES</b>	xv
<b>LIST OF ABBREVIATIONS</b>	xix
<b>CHAPTER</b>	
<b>1 INTRODUCTION</b>	<b>1</b>
1.1 Background	1
1.2 Problem statement	6
1.3 Research objectives	7
1.4 Hypothesis	7
1.5 Significance of study	8
<b>2 LITERATURE REVIEW</b>	<b>9</b>
2.1 History of cannabis	9
2.2 <i>Cannabis sativa</i>	13
2.3 Cannabinoid receptors	15
2.3.1 CB <sub>1</sub> cannabinoid receptor	16
2.3.2 CB <sub>2</sub> cannabinoid receptor	20
2.4 Cannabinoid system in the brain	21
2.4.1 Exogenous cannabinoids	21
2.4.1.1 Delta-9-tetrahydrocannabinol ( $\Delta^9$ THC)	22
2.4.2 Endogenous cannabinoids	25
2.4.3 Endocannabinoid signaling	25
2.5 Cannabinoid receptor antagonist	27
2.5.1 Rimonabant	27
2.6 Role in hippocampus	29
2.7 Neuronal Plasticity	31
2.8 Memory process	32
2.9 Pharmacological effect of $\Delta^9$ THC	35
2.9.1 Tolerance and dependence	35
2.9.2 Adverse effects of cannabis on central nervous system	36
2.10 Extracellular signal-regulated kinase (ERK)	37
2.11 cAMP- response element binding protein (CREB)	39
2.11.1 Regulation of synaptic function by CREB	41
2.12 <i>c-fos</i>	42

<b>3</b>	<b>METHODOLOGY</b>	44
3.1	Subjects	44
3.2	Drug administration	44
3.3	Sample preparation	46
3.4	Western blotting: Measurement of total ERK1, ERK2, p-ERK1, p-ERK2, CREB, p-CREB and <i>c-fos</i> protein levels	48
3.4.1	Preparation of SDS gel	48
3.4.2	Running and transferring the gels	48
3.4.3	Immunoblotting	49
3.4.4	Developing and analyzing the membrane	50
3.4.5	Stripping	50
3.5	Statistical analysis	51
<b>4</b>	<b>RESULTS</b>	52
4.1	Effects of acute $\Delta^9$ THC on ERK1, ERK2, p-ERK1, p-ERK2, CREB, p-CREB and <i>c-fos</i> protein levels in the hippocampus of rats	52
4.2	Effects of chronic $\Delta^9$ THC on ERK1, ERK2, p-ERK1, p-ERK2, CREB, p-CREB and <i>c-fos</i> protein levels in the hippocampus of rats	61
4.3	Effects of the CB <sub>1</sub> antagonist SR141716A on changes in ERK1, ERK2, p-ERK1, p-ERK2, CREB, p-CREB and <i>c-fos</i> protein levels in the hippocampus of rats	70
<b>5</b>	<b>DISCUSSION</b>	79
<b>6</b>	<b>CONCLUSION AND FUTURE RECOMMENDATIONS</b>	90
6.1	Conclusion	90
6.2	Future work and recommendation	92
	<b>REFERENCES</b>	94
	<b>APPENDICES</b>	115
	<b>BIODATA OF STUDENT</b>	126